{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["enfortumab vedotin","pembrolizumab"],["pembrolizumab"]],"indication":"muscle-invasive bladder urothelial carcinoma","name":"RETAIN-3","nct_id":"NCT07908979","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=retain-3-nct07908979. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RETAIN-3","arms":[{"description":"Participants receive neoadjuvant enfortumab vedotin plus pembrolizumab for 3 cycles followed by protocol-specified clinical restaging and biomarker assessment. All enrolled participants begin study treatment in this arm.","label":"Arm A: Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab With Restaging","type":"EXPERIMENTAL"},{"description":"Participants with positive post-treatment circulating tumor DNA (ctDNA) and favorable clinical restaging findings may receive an additional 3 cycles of enfortumab vedotin plus pembrolizumab followed by repeat assessment.","label":"Arm B: Additional Enfortumab Vedotin Plus Pembrolizumab for ctDNA-Positive Participants","type":"EXPERIMENTAL"},{"description":"Participants meeting protocol-defined criteria may undergo active surveillance while receiving maintenance pembrolizumab and scheduled disease evaluations.","label":"Arm C: Maintenance Pembrolizumab With Active Surveillance","type":"EXPERIMENTAL"},{"description":"Participants requiring definitive bladder-directed treatment may receive chemoradiation with radiation therapy and investigator-selected radiosensitizing chemotherapy according to protocol specifications.","label":"Arm D: Definitive Chemoradiation","type":"EXPERIMENTAL"},{"description":"Participants requiring definitive surgical management may undergo radical cystectomy.","label":"Arm E: Radical Cystectomy","type":"EXPERIMENTAL"}],"collaborators":["Natera, Inc."],"completion_date":{"date":"2031-11-01","type":"ESTIMATED"},"conditions":["Bladder Cancer","Urothelial Carcinoma","Muscle-Invasive Bladder Carcinoma","Muscle-invasive Bladder Urothelial Carcinoma"],"enrollment":{"count":70,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Enfortumab vedotin","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Fluorouracil","otherNames":[],"type":"DRUG"},{"name":"Mitomycin c","otherNames":[],"type":"DRUG"},{"name":"Radical cystectomy","otherNames":[],"type":"PROCEDURE"},{"name":"Radiation therapy","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-11-02","lead_sponsor":"Fox Chase Cancer Center","official_title":"GU-254: A Phase II Trial of Risk-Enabled Therapy After Initiating Neoadjuvant Enfortumab Vedotin/Pembrolizumab for Bladder Cancer (RETAIN-3)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"2-Year Metastasis-Free Survival (MFS)","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2026-10-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT07908979"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/retain-3-nct07908979"}